In Western blot, a band is seen at ~16 kDa. This antibody did not work in IHC with mouse tissue or in ICC.
16 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
PBS and 30% Glycerol
0.1% Sodium Azide
Immunogen affinity purified
Alternate Names for CCL2/MCP1 Antibody
C-C motif chemokine 2
chemokine (C-C motif) ligand 2
HC11Monocyte secretory protein JE
MCAFMonocyte chemotactic and activating factor
MCP1 Monocyte chemotactic protein 1
MCP-1 Small-inducible cytokine A2
Monocyte chemoattractant protein 1
monocyte chemoattractant protein-1
small inducible cytokine A2 (monocyte chemotactic protein 1, homologous tomouse Sig-je)
small inducible cytokine subfamily A (Cys-Cys), member 2
MCP-1 (monocyte chemoattracctant protein-1, also called C-C motif chemokine 2 or CCL2) is a secreted protein belonging to intercrine beta (chemokine CC) family and it specifically act as a chemotactic factor to attracts monocytes, CD4+ T cells, NK cells as well as for CCR2 expressing cells, but not neutrophils. Both hematopoietic and non-hematopoietic cells that include monocytes/macrophages, dendritic cells, astrocytes, endothelial cells and fibroblasts express MCP-1, and monocytes/macrophages are the major source of MCP-1 in peripheral blood. Besides, expression at acute inflammation sites, MCP-1 is upregulated in chronic inflammation, including autoimmune disease, atherosclerosis, cancer, and chronic infection. MCP-1 has been implicated in both pro-inflammatory and anti-inflammatory responses, and is a potential intervention point for the treatment of various inflammatory/autoimmune diseases (multiple sclerosis, atherosclerosis, insulin-resistant diabetes, rheumatoid arthritis and lupus nephritis), cancers (breast and prostate cancer) and HIV-1/AIDS.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
FAQs for CCL2/MCP1 Antibody (NBP1-07034). (Showing 1 - 2 of 2 FAQs).
Our customer would like to perform IHC with samples from Rat. She has questions regarding antibodies of choice: 1. Is it possible to use NB400-142 for IHC? 2. I am having difficulty of choosing between NBP1-77679 and NBP1-77680. Would you please help suggest? 3. Although it is described as IHC (-) on the product page of NBP1-07034, This antibody did not work in IHC with mouse tissue is also described. How about Rat samples? Is it possible that the antibody can work in IHC with rat tissues?
To answer your questions about NB400-142, this antibody has not been validated for IHC and we cannot guarantee that it will work. Both NBP1-77679 and NBP1-77680 have been validated for use in rat and IHC. The difference between these 2 antibodies is the immunogen as they were raised against different regions of the protein. Please point out the immunogen to your customer and have them decide what would be best for their research. NBP1-07034 does not work in IHC, it is only guaranteed for Western blot in human, mouse and rat. When an application is followed by a (-) I would not recommend using this application in any species.
Would you please let me know what buffer I should use for WB with antibody (MCP1 Antibody)?
In western blot, we recommend diluting this antibody in 1% non-fat dry milk in TBST (0.1% tween-20). This is the same diluent we use for our secondary antibody. For blocking, we use 5% non-fat dry milk in TBST for 1 hour at room temperature.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.